Krystal Biotech subsidiary Jeune reports up to 9-month durability for KB301 in PEARL-1 extension

Krystal Biotech, Inc.

Up to nine months durability of effect observed in patients aged 55-76 following high dose KB301.
Mean Subject Satisfaction Score change from baseline ranged from 1.6 to 1.85 points at 7-9 months.
Responder rate 62-70% based on Subject Satisfaction Score ≥1 point change; Investigator Assessments showed clinically meaningful difference in 70-76% of treated cheeks.
Plan to initiate Phase 2 PEARL-2 study in 1H 2023 for fine lines and wrinkles.
All adverse events were injection-site related, transitory, mild or moderate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.